CoJourney is a global cell and gene therapy CDMO specializing in end-to-end process development, analytical services, and cGMP manufacturing for advanced therapeutics. Founded in 2021, the company supports biotechnology and pharmaceutical innovators developing plasmids, viral vectors, mRNA, sgRNA, and exosome-based therapies for clinical and commercial applications.

CoJourney’s proprietary and innovative Zero Chrom® plasmid manufacturing platform is designed to deliver high-purity plasmids with improved scalability, reduced contamination risk, faster turnaround times, and significant cost efficiencies compared with traditional chromatography-based approaches. The company specialises in highly efficient viral vector manufacturing platforms and integrated analytical development and QC testing services to accelerate IND-enabling and clinical-stage programs.

With operations in the United States and China, CoJourney operates state-of-the-art GMP facilities compliant with FDA, EMA, and NMPA standards. Its capabilities span process development, GMP manufacturing, release testing, and regulatory support for cell and gene therapy products. The company has supported over 100 clients globally and delivered hundreds of manufacturing batches across a range of advanced therapy modalities.

CoJourney is focused on enabling faster and more cost-effective development pathways for gene therapy companies by combining manufacturing innovation, regulatory expertise, and scalable production infrastructure.